AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 211 min read$UTHR

MAHON PAUL A sold $4.3M of UTHR

MAHON PAUL A (EVP & GENERAL COUNSEL) sold 8,300 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $523.14 ($520.03–$527.21, $4.34M total) across 9 trades on 2026-08-20 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MAHON PAUL A
Published Aug 21, 2026, 8:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 8:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Neutral
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRNeutralLow
01

Why it matters

The disclosed sale reduces the insider's ownership but does not indicate any immediate corporate action.

02

Market read

Primary source filing; modest insider sale may influence short‑term sentiment.

03

What to watch

The 10b5‑1 plan pre‑arranged nature reduces the informational value of the transaction.

Relevance 5/10Novelty 6/10Timing: post‑market 2026‑08‑20 filing

Background

Form 4 filings disclose insider transactions; a senior executive's sale is publicly reported for transparency.

Company-level read

Ticker impact

$UTHRNeutralMedium confidence
Context

EVP & General Counsel Paul Mahon sold 8,300 shares for $4.34M via a 10b5‑1 plan, reducing his stake to 45,172 shares.

Expected impact

Possible modest downward pressure in the near term as the market digests the $4.3M sale.

Evidence & confidence

Insider sales by senior executives are watched by traders; the amount is material for a mid‑cap biotech but not large enough to trigger a sharp move.

Market effects

Sector

May prompt scrutiny of United Therapeutics' insider activity within the biotech sector.

Regional

Limited to U.S. markets where UTHR trades.

Global

Minimal global impact.

Counterpoint

What could challenge this read

The sale could be a routine liquidity move, not a negative signal; the stock may remain stable.

Key entities

  • Company
    United Therapeutics Corp

    Biopharmaceutical company listed on NASDAQ (UTHR).

  • Executive
    Paul Mahon

    EVP & General Counsel of United Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 28
$UTHRMed

United Therapeutics Receives FDA Clearance to Begin Clinical Trial of Inhaled PAH Treatment

United Therapeutics (UTHR) received FDA clearance to start clinical trials for Treprostinil-Iloprost SMI, an inhaled treatment for pulmonary arterial hypertension (PAH). The phase 1 trial will assess safety and tolerability. The therapy aims to address symptom flare-ups between maintenance doses. UTHR plans a phase 2 trial in 2027 if initial results are positive. PAH affects around 500,000 people globally.

finance.yahoo.com2 min
OCT 28
$UTHRMed

FDA clears a trial of a two-drug inhaler that could be the first as-needed therapy for lung artery disease.

The FDA approved a trial for Treprostinil-Iloprost SMI, a potential first as-needed inhaler therapy for pulmonary arterial hypertension (PAH). United Therapeutics plans a phase 1 study in 2026, with a phase 2 study in PAH patients anticipated in 2027. The therapy combines treprostinil and iloprost, aiming to provide episodic symptom relief. United Therapeutics aims to expand its PAH treatment portfolio.

stocktitan.net2 min